Erasca Q3 loss widens as R&D spending rises
ERAS•Erasca’s third-quarter net loss widened year over year as research and development spending increased. The company ended the quarter with $948 million in cash, received FDA Fast Track Designation for ERAS-0015 in metastatic pancreatic cancer, and outlined development milestones for 2026 and 2027.
1. Quarterly results
Erasca reported a third-quarter loss of $0.15 per basic share. Its net loss widened year over year as higher clinical-trial activity, preclinical studies and personnel costs increased research and development expenses. Cash stood at $948 million at quarter-end, up from $342 million at 2025 year-end.
2. Drug development
The FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic cancer. Erasca expects preliminary Phase 1 monotherapy data for ERAS-4001 in the second half of 2026 and Phase 1 monotherapy expansion data for ERAS-0015 in the first half of 2027. It expects to initiate a Phase 3 pivotal trial in first-line pancreatic ductal adenocarcinoma in 2027.
